: Future outlook on bispecific antibodies and combination therapies.
: Review current inhibitors such as Sorafenib or Nintedanib , which block FLT-3 alongside other receptors like VEGFR and PDGFR to treat various cancers.
: Discuss solid dispersion techniques to enhance drug delivery.
: Future outlook on bispecific antibodies and combination therapies.
: Review current inhibitors such as Sorafenib or Nintedanib , which block FLT-3 alongside other receptors like VEGFR and PDGFR to treat various cancers.
: Discuss solid dispersion techniques to enhance drug delivery.